HC Wainwright Rates Invivyd (IVVD) buy, $10 Price Target

HC Wainwright's analyst maintains a buy rating for Invivyd, Inc. with a $10 price target, a 974.11% upside from the current price.

By EarningsIQ Research Desk · Published Jun 16, 2026, 2:05 AM EDT · Updated Jun 18, 2026, 1:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Invivyd, Inc. ($IVVD) "buy" with a $10 price target on June 15, 2026.

Since the rating, $IVVD is up 4.6% after 1 week, down 5.8% after 1 month and down 28.7% to date (from the $0.87 close on Jun 15, 2026).

IVVD Invivyd, Inc.

$0.62 -75.20% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reaffirmed its buy rating on Invivyd, Inc. (IVVD) with a $10 price target on June 15, 2026.
HC Wainwright's $10 price target implies 974.11% upside from Invivyd, Inc.'s ($IVVD) current $0.93 share price.
Invivyd, Inc. trades at $0.77 with a market cap of about $256 million and a 52-week range of $0.48 to $3.07.
Recent insider buying includes multiple purchases of 50,000 shares each by insiders on May 19, 2026.

Get $IVVD trade alerts by text

We text you when insiders, Congress or big funds trade $IVVD. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Invivyd, Inc. alert may contain errors. Disclosures

HC Wainwright has reaffirmed its buy rating on Invivyd, Inc. (NasdaqGM: IVVD), maintaining a price target of $10. The update was made by analyst Patrick R. Trucchio on June 15, 2026. Shares of Invivyd traded at $0.77 following the announcement.

Invivyd, Inc. Stock Up 23.3%

Shares of Invivyd, Inc. currently trade at $0.77 on the NasdaqGM. The company has a market cap of approximately $256 million. Over the past 52 weeks, the stock has ranged from a low of $0.48 to a high of $3.07. It has a 50-day moving average of $1.32 and a 200-day moving average of $1.70. Invivyd's financial ratios show a current ratio of 6.47 and a quick ratio of 6.20, with a debt-to-equity ratio of 4.25.

12-month forecast

$IVVD price target

Invivyd, Inc. daily closes and this analyst's $10 target. Not advice.

Recent Earnings

Invivyd reported revenue of $55.9 million, with a revenue growth rate of 21.6%. However, the company posted a negative net margin of -138.9% and a return on equity of -60.3%. The next earnings report is expected on August 13, 2026.

Insider Buying and Selling at Invivyd, Inc.

Several insiders made significant purchases on May 19, 2026. Royan Ajay, Marc Elia, Kevin McLaughlin, Terrance McGuire, Tamsin Berry, and Paul Bolno each bought 50,000 shares. These transactions were not part of a planned trading program.

Analysts Set New Price Targets

On June 15, 2026, HC Wainwright reiterated its buy rating for Invivyd, Inc. with a price target of $10. BTIG also reaffirmed a buy rating with the same target earlier in the year. The analyst consensus remains strong buy, with an average target price of $10 based on three analyst opinions.

About Invivyd, Inc.

Invivyd, Inc., headquartered in New Haven, Connecticut, operates in the biotechnology sector. The company focuses on developing antibody therapies to prevent and treat viral infectious diseases. Its lead product, Pemivibart, is an investigational monoclonal antibody for COVID-19 prophylaxis. Invivyd is also working on other treatments for SARS-CoV-2 and respiratory viruses.

Bottom Line

HC Wainwright's reaffirmation of a buy rating signals confidence in Invivyd's potential, despite its current challenges. Investors keep an eye on such analyst updates, though it's important to remember that these ratings are based on past data and market conditions can change. Invivyd continues to develop its pipeline with several promising products in various stages.